Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Aligos Therapeutics Inc (ALGS)

Aligos Therapeutics Inc (ALGS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Fri Nov 14, 7:00AM CST

SOUTH SAN FRANCISCO, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient...

ALGS : 10.09 (+2.23%)
Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2025 GlobeNewswire - Mon Nov 10, 7:00AM CST

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class...

ALGS : 10.09 (+2.23%)
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results GlobeNewswire - Thu Nov 6, 7:30AM CST

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through...

ALGS : 10.09 (+2.23%)
Aligos Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire - Tue Nov 4, 7:30AM CST

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class...

ALGS : 10.09 (+2.23%)
Aligos Therapeutics to Announce 3rd Quarter 2025 Financial Results on November 6, 2025 GlobeNewswire - Thu Oct 30, 7:30AM CDT

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class...

ALGS : 10.09 (+2.23%)
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Fri Oct 17, 7:30AM CDT

SOUTH SAN FRANCISCO, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient...

ALGS : 10.09 (+2.23%)
H.C. Wainwright Reaffirms Their Buy Rating on Aligos Therapeutics (ALGS) Tipranks - Thu Oct 16, 9:06AM CDT

In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Aligos Therapeutics, with a price target of $50.00. The company’s shares opened today at $9.18.Elevate Your...

ALGS : 10.09 (+2.23%)
Aligos Therapeutics Receives USAN Council Approval for pevifoscorvir sodium as Nonproprietary Name for ALG-000184 GlobeNewswire - Thu Oct 16, 7:30AM CDT

SOUTH SAN FRANCISCO, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class...

ALGS : 10.09 (+2.23%)
Aligos Therapeutics to Present at the H.C. Wainwright Liver Disease Conference GlobeNewswire - Tue Oct 14, 7:30AM CDT

SOUTH SAN FRANCISCO, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class...

ALGS : 10.09 (+2.23%)
Aligos Therapeutics Announces Eight Abstracts Accepted at The Liver Meeting® 2025 GlobeNewswire - Tue Oct 7, 7:30AM CDT

SOUTH SAN FRANCISCO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class...

ALGS : 10.09 (+2.23%)

Barchart Exclusives

Is This Dividend Stock a Buy for 2026 After Rising 265% in 2025? Barchart - Thu Dec 4, 6:30PM CST
Anglogold Ashanti shares have soared this year amid a spike in gold prices. While the shares might take a breather for now, it is a buy-on-the-dip candidate for 2026. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot